Harman Patil

Verubecestat

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
ATC code  None
Synonyms  MK-8931
PubChem CID  51352361
ChemSpider ID  31399364
Legal status  Investigational
CAS Number  1286770-55-5
UNII  J1I0P6WT7T
Verubecestat httpsnewdrugapprovalsfileswordpresscom2015

Verubecestat


Verubecestat (MK-8931) is an experimental drug for the treatment of Alzheimer's disease. It is an inhibitor of beta-secretase 1 (BACE1).

In April 2012 phase I clinical results were announced. Phase 1b results have also been reported.

As of December 2016 it is in two phase 2/3 clinical trials that have progressed to phase 3. EPOCH, was to complete data collection for the primary outcome measure by June 2017.

In February 2017, Merck halted its late-stage trial of verubecestat for mild to moderate Alzheimer's disease after it was reported as having "virtually no chance of finding a positive clinical effect" according to an independent panel of experts. The results of Merck's trial of verubecestat on patients with prodromal (early stage) Alzheimer's are still expected in February 2019.

References

Verubecestat Wikipedia


Similar Topics
Kaena: The Prophecy
Three Crowns of the Sailor
Azriel Páez
Topics